欢迎来到范德生物BIOFOUNT
范德生物中国

中文范德生物中文语言

范德生物产品购买购物车
0
搜索
Reslizumab_241473-69-8_产品详情
241473-69-8
  • names:

    Reslizumab

  • CAS号:

    241473-69-8

    MDL Number:
  • MF(分子式): MW(分子量):
  • EINECS: Reaxys Number:
  • Pubchem ID: Brand:BIOFOUNT
Reslizumab
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
YZM004509-5mg 5mg ¥ 0.00 ¥ 0.00 Backorder
- +
¥ 0.00
YZM004509-1mg 1mg >97% ¥ 0.00 ¥ 0.00 2-3天
- +
¥ 0.00
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名
英文别名
CAS号 241473-69-8
Inchi
InchiKey
分子式 Formula
分子量 Molecular Weight
溶解度Solubility
性状
储藏条件 Storage conditions 请根据产品建议的存储条件进行存储,Please store the product under the recommended condition sin the description.
Reslizumab(CAS:241473-69-8)实验注意事项:
1.实验前需戴好防护眼镜,穿戴防护服和口罩,佩戴手套,避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生,必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储,并交于专业生物废气物处理公司处理,以免造成环境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
产品说明 Reslizumab (Sch 55700) 为靶向人白介素 5 (IL-5) 的人源化单克隆抗体,用于治疗嗜酸性粒细胞性哮喘
IntroductionReslizumab (Sch 55700) is humanized monoclonal antibodies that targetinterleukin (IL)for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL. Reslizumab inhibitsILependent cell proliferation, with anIC50value of approximately 91.1pM. Reslizumab has high binding affinity for humanIL, withKDvalues of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively[2].
Application1
Application2
Application3
Reslizumab (Sch 55700) 为靶向人白介素 5 (IL-5) 的人源化单克隆抗体,用于治疗嗜酸性粒细胞性哮喘。Reslizumab 可有效阻断IL-5的功能。Reslizumab 抑制IL-5依赖性细胞增殖,IC50值约为 91.1pM。Reslizumab 对人IL-5具有高结合亲和力,在 Biacore 表面等离振子共振和动力学排斥分析中,KD值分别为 109 pM 和 4.3 pM。Reslizumab (Sch 55700) is humanized monoclonal antibodies that targetinterleukin-5 (IL-5)for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function ofIL-5. Reslizumab inhibitsIL-5-dependent cell proliferation, with anIC50value of approximately 91.1pM. Reslizumab has high binding affinity for humanIL-5, withKDvalues of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively[1][2].
警示图
危险性
危险性警示
安全声明
安全防护
备注
【1】.Liddament M, et al. Higher Binding Affinity and in vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab. Allergy Asthma Immunol Res. 2019 Mar;11(2):291-298.
【2】.Pérez de Llano LA, et al. Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab. Allergy. 2019 Sep 4.
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻
        抱歉,暂无数据!
        My title page contents